Company: OSRH
Filing Date: 2025-01-29
Form Type: S-4/A
Source: 0001213900-25-007923
Chunk: 902

Company: OSR Holdings, Inc.
Filing Date: 2025-01-29
Form: S-4/A
Chunk 902
---
 overall innovation. •Collaborative Synergies: Spokes can collaborate with external partners, including academic institutions, research organizations, and other biotech companies in their own fields of expertise and/or strategic interests, to leverage external expertise and resources, fostering a collaborative environment. 6)Speed to Market •Accelerated Development: By decentralizing operational tasks to specialized spokes, companies can streamline processes and accelerate the development and commercialization of products. •Regulatory Efficiency: The hub can focus on navigating complex regulatory environments, ensuring that spokes comply with necessary regulations, which can expedite approvals and market entry. 7)Market Reach and Customer Focus •Localized Operations: Spokes can be established in different geographic regions, allowing the company to tap into local markets, understand regional customer needs, and tailor products and services accordingly. •Customer-Centric Approach: Spokes can focus on specific customer segments or therapeutic areas, ensuring that their operations are closely aligned with customer needs and preferences. In summary, the hub-and-spoke biotech business model can offer competitive advantages in the above listed areas when properly equipped with capable management and sufficient capital. It is our assessment that OSR’s management team has the right capabilities in terms of professional experiences and track records in the capital market, M&A, private equity/venture capital and legal industries, as well as the scientific and clinical development backgrounds and experiences held by the subsidiary founders and management, in order to deploy successfully the hub-and-spoke biotech business model. Annex I-6 5.Fairness Opinion in connection with the Investment Criteria The BLAC Prospectus refers to the following Investment Criteria (“ Investment Criteria ”): We are focused on companies developing the next generation of biologics which include therapeutic antibodies, engineered protein and enzyme drugs, cellular therapies, engineered viruses and bacteria, and DNA- and RNA-modifying technologies, using advanced molecular biology and biochemistry. We will consider companies with pipeline programs in clinical “Proof-of-Concept” studies (often from Phase 1 to 2a) to develop novel medicines to address diseases which cannot yet be cured or sufficiently managed. We seek to create stockholder value by leveraging our management’s and its advisors’ experience and network to efficiently guide an emerging biotech company towards clinical advancement of key assets in their pipeline while helping to secure licensing deals and partnerships with major pharmaceutical companies globally. Consistent with our strategy, we have established the following general criteria and guidelines that we believe are important in evaluating prospective target businesses. While we intend to use these criteria and guidelines in evaluating prospective businesses,